Skip to Main Content

Good morning, everyone, and welcome to another working week. We hope the weekend respite was enjoyable, because that startling routine of deadlines and meetings and what-not has now returned. But you knew this was coming, yes? Avoiding the future is a difficult thing. So please join us as we hoist our ritualistic cup of stimulation and attack the ever-growing to-do list. Meanwhile, here are some tidbits to get you started. Hope you conquer the world today, and do keep us in mind if you hear anything interesting. …

Sanofi (SNY) and GlaxoSmithKline (GSK) announced positive results from a Phase 2 clinical trial of their joint Covid-19 vaccine, saying it generated strong levels of neutralizing antibodies in recipients across all ages studied, and that a large international Phase 3 trial will begin in coming weeks, STAT says. The duo is far behind in the effort to produce a vaccine and lock down markets for their product, having suffered a setback in a Phase 1/2 trial last year. But with global vaccine supplies falling short, they still believe there is a place for their shot.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!